Recent Company News

• 02:59 AM ET Jun 09, 2025
  

  StreetAccount Summary - European pre-market trading update

• 02:56 AM ET Jun 09, 2025
  

  Fresenius Kabi carrying out voluntary recall of IVENIX INFUSION SYSTEM LVP Blood Products Administration Set - FDA announcement, 6-Jun (timing uncertain) (€44.29, 0.00)

• 02:39 AM ET Jun 05, 2025
  

  Citi transfers ALC, ALC.SW, AMP.IM, others

• 04:00 AM ET Jun 03, 2025
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (96 total)

• 08:35 AM ET May 27, 2025
  

  Formycon, Fresenius Kabi announce market launch of FYB202/Otulfi in Canada (€23.05, 0.00)

• 04:11 AM ET May 27, 2025
  

  EMA's CHMP has issued a positive opinion for Fresenius' denosumab biosimilar candidates for the treatment of osteoporosis and other bone-related conditionsFresenius (€43.17, +0.05)

• 08:28 AM ET May 23, 2025
  

  EMA's CHMP has recommended several changes to the way the antibiotic azithromycin is used in the EU, including the removal of certain indications

• 07:46 AM ET May 23, 2025
  

  EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Fresenius's Conexxence (€43.22, -0.15)

• 07:44 AM ET May 23, 2025
  

  EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Bomyntra (€43.22, -0.15)

• 09:03 AM ET May 19, 2025
  

  Formycon, Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi (€22.45, -0.45)